92 related articles for article (PubMed ID: 2684394)
1. Decreased accessibility of globotriaosylceramide associated with decreased tumorigenicity in Burkitt's lymphoma variants induced by immunoselection.
Junqua S; Larsen AK; Wils P; Mishal Z; Wiels J; Le Pecq JB
Cancer Res; 1989 Dec; 49(23):6480-6. PubMed ID: 2684394
[TBL] [Abstract][Full Text] [Related]
2. Comparison of inhibitory effect of galactose analogs on the binding and cytotoxicity of an anti-globotriaosylceramide monoclonal antibody coupled or not coupled to pokeweed antiviral protein.
Junqua S; Wils P; Mishal Z; Le Pecq JB
Eur J Immunol; 1987 Apr; 17(4):459-64. PubMed ID: 2436922
[TBL] [Abstract][Full Text] [Related]
3. Stable nontumorigenic phenotype of somatic cell hybrids between malignant Burkitt's lymphoma cells and autologous EBV-immortalized B cells despite induction of chromosomal breakage and loss.
Jox A; Taquia E; Vockerodt M; Draube A; Pawlita M; Möller P; Bullerdiek J; Diehl V; Wolf J
Cancer Res; 1998 Nov; 58(21):4930-9. PubMed ID: 9810002
[TBL] [Abstract][Full Text] [Related]
4. Properties of immunotoxins against a glycolipid antigen associated with Burkitt's lymphoma.
Wiels J; Junqua S; Dujardin P; Le Pecq JB; Tursz T
Cancer Res; 1984 Jan; 44(1):129-33. PubMed ID: 6690030
[TBL] [Abstract][Full Text] [Related]
5. Enzymatic and organizational difference in expression of a Burkitt lymphoma-associated antigen (globotriaosylceramide) in Burkitt lymphoma and lymphoblastoid cell lines.
Wiels J; Holmes EH; Cochran N; Tursz T; Hakomori S
J Biol Chem; 1984 Dec; 259(23):14783-7. PubMed ID: 6438103
[TBL] [Abstract][Full Text] [Related]
6. Malignant human B cells express two populations of p24 surface antigens.
Pesando JM; Hoffman P; Conrad T
J Immunol; 1986 Apr; 136(7):2709-14. PubMed ID: 3485154
[TBL] [Abstract][Full Text] [Related]
7. Apoptosis induced in Burkitt's lymphoma cells via Gb3/CD77, a glycolipid antigen.
Mangeney M; Lingwood CA; Taga S; Caillou B; Tursz T; Wiels J
Cancer Res; 1993 Nov; 53(21):5314-9. PubMed ID: 8221667
[TBL] [Abstract][Full Text] [Related]
8. A new Mr 55,000 surface protein implicated in melanoma progression: association with a metastatic phenotype.
Boukerche H; Baril P; Tabone E; Bérard F; Sanhadji K; Balme B; Wolf F; Perrot H; Thomas L
Cancer Res; 2000 Oct; 60(20):5848-56. PubMed ID: 11059782
[TBL] [Abstract][Full Text] [Related]
9. Reconstitution of hTERT restores tumorigenicity in melanoma-derived c-Myc low-expressing clones.
Biroccio A; Amodei S; Benassi B; Scarsella M; Cianciulli A; Mottolese M; Del Bufalo D; Leonetti C; Zupi G
Oncogene; 2002 May; 21(19):3011-9. PubMed ID: 12082531
[TBL] [Abstract][Full Text] [Related]
10. Role of the p53 tumor suppressor gene in the tumorigenicity of Burkitt's lymphoma cells.
Cherney BW; Bhatia KG; Sgadari C; Gutierrez MI; Mostowski H; Pike SE; Gupta G; Magrath IT; Tosato G
Cancer Res; 1997 Jun; 57(12):2508-15. PubMed ID: 9192833
[TBL] [Abstract][Full Text] [Related]
11. [A monoclonal antibody, specific for Burkitt's lymphoma, is also a blood group Pk antibody].
Fellous M; Wiels J; Cartron JP; Tursz T
Dev Biol Stand; 1984; 57():293-8. PubMed ID: 6084615
[TBL] [Abstract][Full Text] [Related]
12. Burkitt's lymphoma cell line bearing surface IgA and negative for nuclear antigen of Epstein-Barr virus (EBNA).
Hayashi Y; Matsumura Y; Nishihira T; Watanabe I; Ohi R; Kasai M; Kumagai K; Kamada N
Jpn J Exp Med; 1980 Dec; 50(6):423-34. PubMed ID: 6268866
[TBL] [Abstract][Full Text] [Related]
13. A glycolipid antigen associated with Burkitt lymphoma defined by a monoclonal antibody.
Nudelman E; Kannagi R; Hakomori S; Parsons M; Lipinski M; Wiels J; Fellous M; Tursz T
Science; 1983 Apr; 220(4596):509-11. PubMed ID: 6836295
[TBL] [Abstract][Full Text] [Related]
14. c-Myc over-expression in Ramos Burkitt's lymphoma cell line predisposes to iron homeostasis disruption in vitro.
Habel ME; Jung D
Biochem Biophys Res Commun; 2006 Mar; 341(4):1309-16. PubMed ID: 16466700
[TBL] [Abstract][Full Text] [Related]
15. Expression of surface antigens during the cell cycle in different growth phases of American and African Burkitt's lymphoma cell lines.
Sieverts H; Alabaster O; Goldschmidts W; Magrath I
Cancer Res; 1986 Mar; 46(3):1182-8. PubMed ID: 3080238
[TBL] [Abstract][Full Text] [Related]
16. Anti-CD20- and B-cell receptor-mediated apoptosis: evidence for shared intracellular signaling pathways.
Mathas S; Rickers A; Bommert K; Dörken B; Mapara MY
Cancer Res; 2000 Dec; 60(24):7170-6. PubMed ID: 11156427
[TBL] [Abstract][Full Text] [Related]
17. High c-myc amplification level contributes to the tumorigenic phenotype of the human breast carcinoma cell line SW 613-S.
Lavialle C; Modjtahedi N; Cassingena R; Brison O
Oncogene; 1988 Sep; 3(3):335-9. PubMed ID: 3060796
[TBL] [Abstract][Full Text] [Related]
18. Theophylline induced differentiation provides direct evidence for the deregulation of c-myc in Burkitt's lymphoma and suggests participation of immunoglobulin enhancer sequences.
Sandlund JT; Neckers LM; Schneller HE; Woodruff LS; Magrath IT
Cancer Res; 1993 Jan; 53(1):127-32. PubMed ID: 8416737
[TBL] [Abstract][Full Text] [Related]
19. Flavopiridol induces apoptosis and caspase-3 activation of a newly characterized Burkitt's lymphoma cell line containing mutant p53 genes.
Rapoport AP; Simons-Evelyn M; Chen T; Sidell R; Luhowskyj S; Rosell K; Obrig T; Hicks D; Hinkle PM; Nahm M; Insel RA; Abboud CN
Blood Cells Mol Dis; 2001; 27(3):610-24. PubMed ID: 11482875
[TBL] [Abstract][Full Text] [Related]
20. c-MYC impairs immunogenicity of human B cells.
Schlee M; Schuhmacher M; Hölzel M; Laux G; Bornkamm GW
Adv Cancer Res; 2007; 97():167-88. PubMed ID: 17419945
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
